Loading clinical trials...

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

Impact of Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support on Antagonist ICSI Cycles

NCT05286554•Alexandria University

Summary

Hormonal milieu during implantation is crucial to embryo-endometrium interaction and to the viability of the conceptus. Alterations in the peri-implantation environment are considered to impair perinatal outcomes in intracytoplasmic sperm injection (ICSI) therapy. GnRH-a is a new and promising modality for LPS. Regimens for using GnRH-a in LPS, including single mid-luteal bolus or the addition of a GnRH-a to progesterone supplementation, have been recently suggested. The aim of this study is to evaluate the impact of addition of mid-luteal single-dose or multiple-dose GnRH agonist to the routine luteal phase support in patients undergoing ICSI cycles using GnRH antagonist protocol.

Eligibility

Age

20 - 38 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Patient age ≤ 38 years.
•2. BMI ≤ 30.
•3. Basal follicle stimulating hormone (FSH) level ≤ 10 IU/L.
•4. Anti-Müllerian hormone (AMH): ≤ 5 ng/ml.

Exclusion Criteria

•1. Endometriosis.
•2. Polycystic ovarian syndrome (PCOS).
•3. Uterine pathology or anomaly.
•4. Evidence of hydrosalpinx by hysterosalpingography or ultrasound.
•5. Comorbidities: Diabetes mellitus, hypertension, immune diseases.

Locations (1)

Alexandria University

Alexandria, Alexandria Governorate, Egypt

Key Dates

Start Date

March 17, 2022

Primary Completion Date

October 27, 2023

Completion Date

January 18, 2024

Last Updated

January 29, 2025

Enrollment

ACTUAL participants

Conditions

Female Infertility

Interventions

gonadotropin releasing hormone-agonist

DRUG

Progesterone

DRUG

Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).

NCT06921395

Female Infertility

View study

RECRUITINGNA

Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.

NCT06629636

Repeated IVF FailureFemale Infertility

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

Inclusion Criteria

Exclusion Criteria

Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).

Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.

Female Fertility, Environmental Agents and Stress Oxidant

Biobank Aimed to Study Gynecological Pathologies, of Male and Female Infertility and Pregnancy Pathologies

Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment

Presence of Toxins from Smoking in the Follicular Fluid of Women Undergoing Intracytoplasmic Sperm Injection Treatment